fgf 2 antibody  (Santa Cruz Biotechnology)

Journal: Frontiers in Immunology

Article Title: Fibroblasts as key effectors of acupuncture in treatment of rheumatoid arthritis

doi: 10.3389/fimmu.2026.1715313

Figure Lengend Snippet: Effects of manual acupuncture at ST36 on local morphology, extracellular matrix remodeling, mechanosensitive molecules, and fibroblast growth factor expression. (A) Representative hematoxylin and eosin staining images of the ST36 acupoint tissue, illustrating structural features and inflammatory status (n = 6; scale bars = 100 μm). (B) Alcian Blue staining of the ST36 region, highlighting glycosaminoglycan distribution in the extracellular matrix (n = 6; scale bars = 100 μm). (C) Masson’s trichrome staining showing collagen fiber organization within the ST36 fascia (n = 6; scale bars = 100 μm). (D–M) mRNA expression levels of ECM- and mechanotransduction-related genes in ST36 tissues, including Piezo1, RhoA, YAP1, Col1a1, HAS2, TNC, FMOD, CB2, FSP-1, and FGF-2, as assessed by RT-qPCR (n = 6). (N) Representative immunohistochemical staining images of the ST36 acupoint showing expression levels of Piezo1. (n = 6; scale bars = 100 μm). (O) Quantitative analysis of immunohistochemical staining intensities for Piezo1. (P) Representative immunohistochemical staining images of the ST36 acupoint showing expression levels of RhoA. (n = 6; scale bars = 100 μm). (Q) Quantitative analysis of immunohistochemical staining intensities for RhoA. (R) Representative immunohistochemical staining images of the ST36 acupoint showing expression levels of YAP1. (n = 6; scale bars = 100 μm). (S) Quantitative analysis of immunohistochemical staining intensities for YAP1. Data are presented as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control group. #p < 0.05, ##p < 0.01, ###p < 0.001 vs. CFA group. ns, not significant.

Article Snippet: Without further washing, sections were incubated overnight at 4 °C on a horizontal shaker with primary antibodies diluted in PBS (1:200), including: RHO-A (1:200, cat. no. sc-418, Santa Cruz Biotechnology, USA); Fibromodulin (1:200, cat. no. sc-25857, Santa Cruz Biotechnology); PCNA (1:200, cat. no. NCL-L-PCNA, Leica Biosystems, UK); HABP (1:200, cat. no. 385911, FUJIFILM Wako, Japan); Cannabinoid Receptor 2 (1:200, cat. no. 703485, Merck, Germany); S100A4 (1:200, cat. no. MA5-32347, Thermo Fisher Scientific, USA); Piezo1 (1:200, cat. no. PA5-72974, Thermo Fisher Scientific); Collagen I (1:200, cat. no. MA1-26771, Thermo Fisher Scientific); FGF-2 (1:200, cat. no. sc-74412, Santa Cruz Biotechnology); YAP1 (1:200, cat. no. ab39361, Abcam, UK).

Techniques: Expressing, Staining, Quantitative RT-PCR, Immunohistochemical staining, Control

Journal: Frontiers in Immunology

Article Title: Fibroblasts as key effectors of acupuncture in treatment of rheumatoid arthritis

doi: 10.3389/fimmu.2026.1715313

Figure Lengend Snippet: Manual acupuncture at ST36 alters local protein expression. (A) Representative immunohistochemical staining images of the ST36 acupoint showing expression levels of Collagen (I) (n = 6; scale bars = 100 μm). (B) Quantitative analysis of immunohistochemical staining intensities for Collagen I. (C) Representative immunohistochemical staining images of the ST36 acupoint showing expression levels of HABP2. (n = 6; scale bars = 100 μm). (D) Quantitative analysis of immunohistochemical staining intensities for HABP2. (E) Representative immunohistochemical staining images of the ST36 acupoint showing expression levels of FMOD. (n = 6; scale bars = 100 μm). (F) Quantitative analysis of immunohistochemical staining intensities for FMOD. (G-I) Representative immunohistochemical staining images of the ST36 acupoint showing expression levels of PCNA, CB2, and FSP-1. (n = 6; scale bars = 100 μm). (J-L) Quantitative analysis of immunohistochemical staining intensities for PCNA, CB2, and FSP-1. (M, N) Representative immunohistochemical staining images of the ST36 acupoint showing expression levels of FGF-2, and FGF-7. (n = 6; scale bars = 100 μm). (O, P) Quantitative analysis of immunohistochemical staining intensities for FGF-2, and FGF-7. Data are presented as the mean ± SEM. * p < 0.05, ** p < 0.01, **** p < 0.0001 vs. control group. # p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.0001 vs. CFA group. ns, not significant.

Article Snippet: Without further washing, sections were incubated overnight at 4 °C on a horizontal shaker with primary antibodies diluted in PBS (1:200), including: RHO-A (1:200, cat. no. sc-418, Santa Cruz Biotechnology, USA); Fibromodulin (1:200, cat. no. sc-25857, Santa Cruz Biotechnology); PCNA (1:200, cat. no. NCL-L-PCNA, Leica Biosystems, UK); HABP (1:200, cat. no. 385911, FUJIFILM Wako, Japan); Cannabinoid Receptor 2 (1:200, cat. no. 703485, Merck, Germany); S100A4 (1:200, cat. no. MA5-32347, Thermo Fisher Scientific, USA); Piezo1 (1:200, cat. no. PA5-72974, Thermo Fisher Scientific); Collagen I (1:200, cat. no. MA1-26771, Thermo Fisher Scientific); FGF-2 (1:200, cat. no. sc-74412, Santa Cruz Biotechnology); YAP1 (1:200, cat. no. ab39361, Abcam, UK).

Techniques: Expressing, Immunohistochemical staining, Staining, Control